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Abstract In the pathogenesis of sepsis, inflammation and
coagulation play a pivotal role. Increasing evidence points
to an extensive cross-talk between these two systems,
whereby inflammation not only leads to activation of
coagulation but coagulation also considerably affects
inflammatory activity. The intricate relationship between
inflammation and coagulation may not only be relevant for
vascular atherothrombotic disease in general but has in
certain clinical settings considerable consequences, for
example in the pathogenesis of microvascular failure and
subsequent multiple organ failure, as a result of severe
infection and the associated systemic inflammatory re-
sponse. Molecular pathways that contribute to inflammation-
induced activation of coagulation have been precisely
identified. Pro-inflammatory cytokines and other mediators
are capable of activating the coagulation system and down-
regulating important physiological anticoagulant pathways.
Activation of the coagulation system and ensuing thrombin
generation is dependent on an interleukin-6-induced
expression of tissue factor on activated mononuclear cells
and endothelial cells and is insufficiently counteracted by
physiological anticoagulant mechanisms and endogenous
fibrinolysis. Interestingly, apart from the overall systemic
responses, a differential local response in various vascular
beds related to specific organs may occur.
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Introduction
Most critically ill patients have an activated coagulation
system. This activation of coagulation is measurable with
highly sensitive assays for molecular markers of activated
coagulation proteases, their activation peptides, or prote-
ase–protease inhibitor complexes [1]. In many patients, this
activation may go undetected, although in the majority of
them some abnormality in routine coagulation tests such as
a drop in platelet count or a minor prolongation of global
coagulation tests may occur. Most clinicians do not regard
these abnormalities very relevant. In more severe forms of
coagulation activation, however, it is now clear that the
ensuingformationofintravascularfibrinmaycontributetothe
pathogenesis of multipleorgan failure, in particularinpatients
with a systemic inflammatory response, for example due to
severe infection or trauma [2]. Indeed, in the majority of
patients with disseminated intravascular coagulation, fibrin
thrombi can be found in many organs (Table 1)[ 3, 4].
The pathogenesis of the systemic activation of
coagulation and microvascular fibrin formation has
become more clear in recent years [5]. The trigger for
the activation of the coagulation system is mediated by
several pro-inflammatory cytokines, expressed and re-
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bin generation proceeds via the (extrinsic) tissue factor/
factor VIIa route and simultaneously occurring depression
of inhibitory mechanisms, such as antithrombin III and the
protein C and S system. Also, impaired fibrin degradation,
due to high circulating levels of PAI-1, contributes to
enhanced intravascular fibrin deposition.
Clinical importance of the interaction
between inflammation and coagulation
There is evidence that activation of coagulation in concert
with inflammatory activation can result in microvascular
thrombosis and thereby contribute to multiple organ failure
in patients with severe sepsis [6]. Firstly, there are several
reports of post-mortem findings in septic patients with
coagulation abnormalities and DIC [7, 8]. These autopsy
findings include diffuse bleeding at various sites, hemor-
raghic necrosis of tissue, microthrombi in small blood
vessels, and thrombi in mid-size and larger arteries and
veins. The demonstration of ischemia and necrosis was
associated with fibrin deposition in small and mid-size
vessels of various organs [9]. Importantly, the presence of
these intravascular thrombi appears to be clearly and
specifically related to the development of organ dysfunc-
tion. Secondly, experimental animal studies of DIC show
fibrin deposition in various organs. Experimental bacter-
emia or endotoxemia causes intra- and extravascular fibrin
deposition in kidneys, lungs, liver, brain, and various other
organs. Amelioration of the hemostatic defect by various
interventions in these experimental models appears to
improve organ failure and, in some but not all cases,
mortality [10–13]. Interestingly, some studies indicate that
amelioration of the systemic coagulation activation will
have a profound beneficial effect on resolution of local
fibrin deposition and improvement of organ failure [14, 15].
Lastly, clinical studies support the notion of coagulation as
an important determinant of clinical outcome. DIC has
shown to be an independent predictor of organ failure and
mortality [2, 16]. In a consecutive series of patients with
severe sepsis, the mortality of patients with DIC was 43%,
as compared with 27% in those without DIC. In this study,
mortality was also directly related to the severity of the
coagulopathy in septic patients [17].
Apart from microvascular thrombosis and organ dys-
function, coagulation abnormalities may also have other
harmful consequences. For example, thrombocytopenia in
patients with sepsis confers an increased risk of bleeding
[18]. Indeed, in particular critically ill patients with a
platelet count of <50×10
9/l have a 4- to 5-fold higher risk
for bleeding as compared to patients with a higher platelet
count [19, 20]. The risk of intracerebral bleeding in patients
in the intensive care unit (ICU) is relatively low (0.3–
0.5%), but in 88% of patients with this complication the
platelet count is less than 100×10
9/l [21]. Regardless of the
cause, thrombocytopenia is an independent predictor of
ICU mortality in multivariate analyses with a relative risk
of 1.9 to 4.2 in various studies [19, 22, 23]. In particular, a
sustained thrombocytopenia during more than 4 days after
ICU admission or a drop in platelet count of >50% during
ICU stay is associated with a 4- to 6-fold increase in
mortality [19, 24]. The platelet count was shown to be a
stronger predictor for ICU mortality than composite scoring
systems, such as the Acute Physiology and Chronic
Evaluation (APACHE) II score or the Multiple Organ
Dysfunction Score (MODS). Also, low levels of coagula-
tion factors in patients with sepsis, as reflected by
prolonged global coagulation times, may be a risk factor
for bleeding and mortality. A PT or aPTT ratio >1.5 in
critically ill patients was found to predict excessive
bleeding and increased mortality [25, 26].
Initiation and propagation of inflammation-induced
activation of coagulation
Tissue factor plays a central role in the initiation of
inflammation-induced coagulation [27]. Blocking tissue
factor activity completely inhibits inflammation-induced
thrombin generation in models of experimental endotox-
emia or bacteremia [12, 28]. The vast majority of cells
constitutively expressing tissue factor are found in tissues
not in direct contact with blood, such as the adventitial
layer of larger blood vessels. However, tissue factor comes
into contact with blood when the integrity of the vessel wall
is disrupted or when endothelial cells and/or circulating
blood cells start expressing tissue factor. The in vivo
expression of tissue factor seems mostly dependent on IL-
6, as demonstrated in studies showing that inhibition of IL-
6 completely abrogates tissue factor-dependent thrombin
Table 1 Organ involvement by (micro)thrombi in patients with
disseminated intravascular coagulation
Organ Mean percentage of patients with (micro)thrombi at autopsy
Kidney 70.4
Lung 70.0
Brain 41.1
Heart 40.4
Liver 39.6
Spleen 39.6
Adrenals 37.1
Pancreas 24.1
Gut 20.7
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inhibition of other pro-inflammatory cytokines had less or no
effect [29, 30]. Inflammatory cells in atherosclerotic plaques
produce abundant tissue factor and upon plaque rupture there
is extensive tissue factor exposure to blood [31]. In severe
sepsis, mononuclear cells, stimulated by pro-inflammatory
cytokines, express tissue factor, which leads to systemic
activation of coagulation [32]. Even in experimental low-
dose endotoxemia in healthy subjects, a 125-fold increase in
tissue factor mRNA levels in blood monocytes can be
detected [33]. A potential alternative source of tissue factor
may be endothelial cells, polymorphonuclear cells, and other
cell types. It is hypothesized that tissue factor from these
sources is shuttled between cells through microparticles
derived from activated mononuclear cells [34]. It is,
however, unlikely that these cells actually synthesize tissue
factor in substantial quantities [32, 35].
Upon exposure to blood, tissue factor binds to factor VIIa.
The complex of tissue factor–factor VIIa catalyzes the
conversion of factor X to Xa, which will form the prothrom-
binase complex with factor Va, prothrombin (factor II) and
calcium, thereby generating thrombin (factor IIa). One of the
key functions of thrombin is to convert fibrinogen into fibrin.
The tissue factor–factor VIIa complex can also activate factor
IX, forming a tenase complex with activated factor IX and
factor X, generating additional factor Xa, thereby forming an
essential amplification loop. The assembly of the prothrombi-
nase and tenase complex is markedly facilitated if a suitable
phospholipid surface is available, ideally presented by
activated platelets. In the setting of inflammation-induced
activationofcoagulation,plateletscanbeactivateddirectlyby
endotoxin or by pro-inflammatory mediators, such as platelet
activating factor. Thrombin itself is one of the strongest
platelet activators in vivo.
Activation of platelets may also accelerate fibrin forma-
tion by another mechanism. The expression of TF on
monocytes is markedly stimulated by the presence of
platelets and granulocytes in a P-selectin-dependent reac-
tion [36]. This effect may be the result of nuclear factor
kappa B (NF-κB) activation induced by binding of
activated platelets to neutrophils and mononuclear cells
[37]. This cellular interaction also markedly enhances the
production of Il-1b, Il-8, MCP-1, and TNF-α [38]. The
expression of P-selectin on the activated platelet membrane
will mediate the adherence of platelets to endothelial cells
and leukocytes [39].
Downregulation of physiological anticoagulant
and fibrinolytic pathways during inflammation
Procoagulant activity is regulated by three important
anticoagulant pathways: antithrombin (AT), the protein C
system, and tissue factor pathway inhibitor (TFPI). During
inflammation-induced activation of coagulation, the func-
tion of all three pathways can be impaired [40] (Fig. 1).
The serine protease inhibitor antithrombin is the main
inhibitor of thrombin and factor Xa. Without heparin, AT
neutralizes coagulation enzymes in a slow, progressive
manner [41]. Heparin induces conformational changes in
AT that result in at least a 1,000-fold enhancement of AT
activity. Thus, the clinical efficacy of heparin is attributed to
its interaction with AT. Endogenous glycosaminoglycans,
such as heparan sulfates, on the vessel wall also promote
AT-mediated inhibition of thrombin and other coagulation
enzymes. During severe inflammatory responses, AT levels
are markedly decreased owing to impaired synthesis (as a
result of a negative acute phase response), degradation by
elastase from activated neutrophils, and—quantitatively
most importantly—consumption as a consequence of
ongoing thrombin generation [42]. Pro-inflammatory cyto-
kines can also cause reduced synthesis of glycosaminogly-
cans on the endothelial surface, which will also contribute
to reduced AT function, since these glycosaminoglycans can
act as physiological heparin-like cofactors of AT [43].
Activated protein C (APC) appears to play a central role
in the pathogenesis of sepsis and associated organ dysfunc-
tion [44]. There is ample evidence that an insufficient
functioning of the protein C pathway contributes to the
derangement of coagulation in sepsis [45, 46]. In patients
with severe inflammation, the protein C system is malfunc-
tioning at virtually all levels. First, plasma levels of the
zymogen protein C are low or very low due to impaired
synthesis, consumption, and degradation by proteolytic
enzymes, such as neutrophil elastase [47–49]. Furthermore,
a significant downregulation of thrombomodulin, caused by
pro-inflammatory cytokines such as TNF-α and IL-1, has
been demonstrated, resulting in diminished protein C
activation [50, 51]. Low levels of free protein S may
further compromise an adequate function of the protein C
system. In plasma, 60% of the co-factor protein S is
complexed to a complement regulatory protein, C4b
binding protein (C4bBP). Increased plasma levels of
C4bBP as a consequence of the acute phase reaction in
inflammatory diseases may result in a relative protein S
deficiency, which further contributes to a procoagulant state
during sepsis. Although it has been shown that the β-chain
of C4bBP (which mainly governs the binding to protein S)
is largely unaffected during the acute phase response [52],
support for this hypothesis comes from studies showing that
the infusion of C4bBP in combination with a sublethal dose
of Escherichia coli into baboons resulted in a lethal
response with severe organ damage due to DIC [53].
Finally, but importantly, in sepsis the EPCR has shown to
be downregulated, which may further negatively affect the
function of the protein C system [54]. Apart from these
Semin Immunopathol (2012) 34:167–179 169effects, sepsis may cause a resistance toward APC by
other mechanisms, which are partly dependent on a
sharp increase in factor VIII levels (released from
endothelial cells), but partly occur by yet unidentified
mechanisms [55].
A third inhibitory mechanism of thrombin generation
involves TFPI, the main inhibitor of the tissue factor–factor
VIIa complex. The role of TFPI in the regulation of
inflammation-induced coagulation activation is not com-
pletely clear. Experiments showing that administration of
recombinant TFPI (and thereby achieving higher than
physiological plasma concentrations of TFPI) blocks
inflammation-induced thrombin generation in humans, and
the observation that pharmacological doses of TFPI are
capable of preventing mortality during systemic infection
and inflammation suggests that high concentrations of TFPI
are capable of importantly modulating tissue factor-
mediated coagulation [10, 56].
Fig. 1 Endothelium-associated mediators of coagulation and inflam-
mation. Panel (a) depicts the normal situation in which the
endothelium expresses thrombomodulin (TM) (activated by thrombin)
and endothelial PC receptor (EPCR), which generate activated PC
(APC). Other anticoagulant factors are tissue factor pathway inhibitor
(TFPI) and antithrombin (AT) attached to the endothelial surface and
from endothelium released tissue-type plasminogen activator (tPA),
which promotes fibrinolysis. b Systemic activation of inflammation
leads to cytokine release and endothelial perturbation, resulting in
release of microparticles (MPs), apoptosis, detachment of endothelial
cells, and loss of barrier function. Coagulation is activated by
induction of tissue factor (TF) on monocytes, MPs, and endothelium
and by release of von Willebrand factor (vWF), which adds to platelet
adhesion to the subendothelial surface. Production of glycosamino-
glycans (GAGs) is downregulated, and the anticoagulant proteins
TFPI, AT, EPCR, and TM are cleaved from the endothelial surface and
are impaired in action. Fibrinolysis is impaired as a result of a rise in
the main inhibitor of the PA (PAI-1), which outweighs a rise in t-PA,
and complement activation is enhanced by loss of activation of
thrombin-activatable fibrinolysis inhibitor (TAFI), which normally
inhibits complement factor C3a and C5a and bradykinin activity.
Anticoagulant proteins in turn modulate cytokine release: tissue
factor–factor VIIa (TF-FVIIa), factor (F) Xa, and thrombin exert
pro-inflammatory activity by cleaving mainly protease activated
receptor (PAR)-1 and PAR-2. APC cleaves PAR-1 in an EPCR-
dependent manner and hereby modulates inflammation and apoptosis
[27]
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during inflammation are TNF-α and IL-1β [57]. Occurrence
of these cytokines in the circulation leads to the release of
plasminogen activators, in particular tissue-type plasminogen
activator (t-PA) and urokinase-type plasminogen activa-
tor (u-PA), from storage sites in vascular endothelial
cells. However, this increase in plasminogen activation and
subsequent plasmin generation is counteracted by a delayed
but sustained increase in plasminogen activator inhibitor type
1( P A I - 1 )[ 58]. The resulting effect on fibrinolysis is a
complete inhibition and, as a consequence, inadequate fibrin
removal, contributing to microvascular thrombosis. Experi-
ments in mice with targeted disruptions of genes encoding
components of the plasminogen–plasmin system confirm
that fibrinolysis plays a major role in inflammation. Mice
with a deficiency of plasminogen activators have more
extensive fibrin deposition in organs when challenged with
endotoxin, whereas PAI-1 knockout mice, in contrast to wild-
type controls, have no microvascular thrombosis upon
endotoxin administration [59].
Modulation of inflammation by coagulation in vivo
Communication between inflammation and coagulation is
bidirectional, such that coagulation can also modulate
inflammatory activity. Coagulation proteases and protease
inhibitors not only interact with coagulation protein
zymogens but also with specific cell receptors to induce
signaling pathways (Fig. 1). In particular, protease inter-
actions that affect inflammatory processes may be impor-
tant in critically ill patients. In vivo evidence for a role of
coagulation–protease stimulation of inflammation comes
from experiments showing that the administration of
recombinant factor VIIa to healthy human subjects causes
a small but significant 3- to 4-fold rise in plasma levels of
IL-6 and IL-8 [60].
A pivotal mechanism by which coagulation proteases
modulate inflammation is by binding to protease activated
receptors or PARs. Four types (PAR 1–4) have been
identified, all belonging to the family of transmembrane
domain, G-protein-coupled receptors [61]. A typical feature
of PARs is that they serve as their own ligand. Proteolytic
cleavage by an activated coagulation factor leads to
exposure of a neo-amino terminus, which activates the
same receptor (and possibly adjacent receptors), initiating
transmembrane signaling. PARs are localized in the vascu-
lature on endothelial cells, mononuclear cells, platelets,
fibroblasts, and smooth muscle cells [61]. PARs 1, 3, and 4
are thrombin receptors, and PAR-1 can also serve as
receptor for the tissue factor–factor VIIa complex and
factor Xa. PAR-2 cannot bind thrombin, but can be
activated by the tissue factor–factor VIIa complex or factor
Xa. Binding of thrombin to its cellular receptor may induce
the production of several cytokines and growth factors.
Binding of tissue factor–factor VIIa to PAR-2 also results in
upregulation of inflammatory responses (production of
reactive oxygen species and expression of MHC class II
and cell adhesion molecules) in macrophages and was
shown to affect neutrophil infiltration and pro-inflammatory
cytokine (TNF-α,I L - 1 β) expression. The in vivo relevance
of PARs has been confirmed in various experimental studies
using PAR inhibitors or PAR-deficient mice [62–64].
Effects of anticoagulant molecules on inflammation
Antithrombin possesses anti-inflammatory properties, many
of which are mediated by its actions in the coagulation
cascade [65]. Most importantly, thrombin inhibition by AT
blunts activation of many inflammatory mediators. For
example, thrombin activates platelets and endothelial cells,
w h i c hi nt u r nc o n t r i b u t eto local inflammation [66].
Activated platelets secrete inflammatory mediators such as
IL-1, which stimulate leukocyte activity. In particular,
recruitment and adhesion of neutrophils and monocytes to
blood vessels within the microcirculation promote inflam-
mation. Increasing evidence suggests that AT possesses
potent anti-inflammatory properties independent of its
anticoagulation activity [66]. Most of these effects have
been demonstrated in vitro or in vivo at high concentrations.
Nevertheless, these mechanisms may be important in
clinical settings that are driven by a combined activation
of inflammation and coagulation. Perhaps most importantly,
AT induces prostacyclin release from endothelial cells [67–
69]. Prostacyclin inhibits platelet activation and aggrega-
tion, blocks neutrophil tethering to blood vessels, and
decreases endothelial cell production of various cytokines
and chemokines [70]. Additional anti-inflammatory actions
of AT are mediated by direct interaction with leukocytes and
lymphocytes. Antithrombin binds to receptors, such as
syndecan-4, on the cell surfaces of neutrophils, monocytes,
and lymphocytes, and blocks the interaction of these cells
with endothelial cells [27]. Inhibition of leukocyte–endo-
thelial cell interactions by AT may be mediated by
prostacyclin release, downregulation of P-selectin, or
prevention of leukocyte activation. Thus, AT directly
hinders leukocyte migration and adhesion to endothelial
cells, which in turn impacts the severity of capillary leakage
and subsequent organ damage. Given the wide-ranging
impact of AT on coagulation and inflammation, there are
multiple potential clinical applications of AT in different
clinical settings that encompass thrombotic states generally
not associated with inflammation (e.g., pregnancy) and in
coagulation-related disease states with powerful pro-
inflammatory elements (e.g., sepsis).
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important regulator of coagulation activity components of
the protein C system also have an important function in
modulating inflammation [71, 72]. APC plays an important
role in attenuating the systemic inflammatory response in
sepsis as demonstrated in experiments showing that block-
ing the protein C pathway in septic baboons exacerbated
the inflammatory response. In contrast, administration of
APC ameliorated the inflammatory activation upon the
intravenous infusion of E. coli [13]. Similar experiments in
rodents showed identical results and demonstrated a
beneficial effect on inflammatory effects in various tissues
[73]. Support for the notion that APC has anti-inflammatory
properties comes from in vitro observations, demonstrating
an APC binding site on monocytes, that may mediate
downstream inflammatory processes [74, 75] and from
experiments showing that APC can block NF-κB nuclear
translocation, which is a prerequisite for increases in pro-
inflammatory cytokines and adhesion molecules [76].
These in vitro findings are supported by in vivo studies in
mice with targeted disruption of the protein C gene. In these
mice with genetic deficiencies of protein C, endotoxemia
was associated with a more marked increase in pro-
inflammatory cytokines and other inflammatory responses
as compared with wild-type mice [77, 78].
It is likely that the effects of APC on inflammation are
mediated by the EPCR [71]. Binding of APC to EPCR
influences gene expression profiles of cells by inhibiting
endotoxin-induced calcium fluxes in the cell and by
blocking NF-κB nuclear translocation [75, 76]. Blocking
the EPCR with a specific monoclonal antibody aggravates
both the coagulation and the inflammatory response to E.
coli infusion [54].
Apart from its effect on cytokine levels, APC has been
shown to inhibit leukocyte chemotaxis and adhesion of
leukocytes to activated endothelium [79, 80]. This notion
was confirmed in a hamster endotoxemia model at concen-
trations of recombinant human APC (rhAPC) that preclude
a significant anticoagulant effect [81]. Moreover, in a
human model of endotoxin-induced pulmonary inflamma-
tion, systemic administration of rhAPC resulted in signif-
icant local anti-inflammatory effects [82]. A potential
mechanism is that APC inhibits expression of platelet-
derived growth factor in the lung [83]. In addition, it has
been shown that APC protects against the disruption of
endothelial cell barrier in sepsis, probably by interfering
with EPCR and PAR-1 on endothelial cells [84–86].
Systemic versus localized responses
Although the mechanisms mentioned above have been
demonstrated to occur in vivo as a general response upon
pro-inflammatory stimuli, it is likely that marked differ-
ences in the procoagulant response as well as the
underlying pathogenetic pathway may exist between cells
and tissues [87]. This may be caused by differences in cell-
specific gene expression, environmental factors, and organ-
specific differences. First, localization of coagulation
activity may relate to a cell-specific gene expression. For
example, inflammatory mediators enhance PAI-1 gene
expression in a complex and tissue-specific way [88].
Recent studies have demonstrated that the von Willebrand
factor promoter contains cell-specific elements, and similar
response elements may be involved in protein synthesis in
cells in general [89]. Second, the tissue environment may
determine whether specific gene transcription occurs [90].
It is not completely clear why specific sites and organs are
at greater risk of developing microvascular thrombosis and
also local differences in the consequences of (micro)
thrombosis are still poorly understood. Environmental
factors underlying the inflammatory response are thought
to play a role in this differential coagulative response as
well. In mice with disturbances in the plasminogen–plasmin
system subjected to hypoxia, the formation of fibrin is
induced and is particularly evident in the lungs [59]. In
contrast, these same mice respond to endotoxemia with
fibrin deposition in the microvasculature of the kidney in
particular. Similarly, mice with a functional thrombomodu-
lin deficiency had a marked increase in pulmonary fibrin
deposition after hypoxic challenge [91]. In addition, when
mice with a functional defect in the thrombomodulin gene
were challenged with endotoxin in sublethal amounts, fibrin
formation was apparent in the lungs, but not in any other
organ studied. In the latter model, fibrin was only
temporarily present, and had disappeared after 24 h [92].
These models illustrate the assumption that fibrin formation
is a localized phenomenon rather than a generalized
process.
Lastly, various organ systems may markedly differ in
their endothelial cell response towards inflammation and
injury. In general, endothelial cells play a central role in the
coagulation response upon systemic inflammation [42]. The
endothelium plays a central role in all major pathways
involved in the pathogenesis of hemostatic derangement
during severe inflammation. Endothelial cells appear to be
directly involved in the initiation and regulation of
thrombin generation and the inhibition of fibrin removal.
Endothelial cells may express tissue factor, which is the
main initiator of coagulation. In addition, physiological
anticoagulant pathways, such as antithrombin, the protein C
system, or tissue factor pathway inhibitor (TFPI), are
mostly located on endothelial cells and endothelial cell
dysfunction is directly related to impaired regulation of
coagulation. Also, endothelial cells are the main storage site
of plasminogen activators and inhibitors and can acutely
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nolytic activity or inhibition. Pro-inflammatory cytokines
are crucial in mediating these effects on endothelial cells,
which themselves may also express cytokines, thereby
amplifying the coagulative response [30]. Although not
completely clear, various organs may differ in all these
endothelial cell-related factors influencing local coagulation
activation and fibrin deposition.
Organ-specific responses by endothelial cells
In their excellent overview, Rosenberg and Aird postulate that
endothelial cells integrate different extracellular signals and
cellular responsesindifferentregions ofthe vascularbed[89].
Various exogenous stimuli, such as shear stress, inflamma-
tory mediators, and growth factors, exert their action on
endothelial cells, and the response of the endothelial cells to
transduce the signal may vary between various tissues and
even from endothelial cell to endothelial cell within a tissue.
As a result, the pro- or anticoagulant response of endothelial
cells may differ between organs. Experiments in mice with a
targeted deletion of the anticoagulant part of the thrombo-
modulin gene show abundant fibrin formation in lungs,
heart, and spleen [93]. Mice with homozygous deficiencies
of plasminogen activators form clots in liver, heart, and
lungs, but not in brain or kidneys [94]. Plasminogen activator
inhibitor-deficient mice have fibrin deposition predominantly
in kidneys [88]. Rosenberg and Aird state that various
mechanisms play a role in the individual response of
endothelial cells. Cell-to-cell communication may have
important effects, as evidenced by the fact that PAI-1
expression in endothelial cells is upregulated if the culture
is incubated with medium from aorta or umbilical vein cell
culture but, in contrast, is downregulated by addition of
conditioned medium from vascular smooth muscle cells [95,
96]. In addition, cell signaling pathways may vary between
endothelial cell subtypes. For example, hemodynamic
changes may have opposite reactions in nitric oxide mRNA
expression in endothelial cells from the aorta or from the
p u l m o n a r ya r t e r y[ 97]. Another example is provided by the
experiment showing that endothelial cells from renal and
cerebrovascular vessels have decreased prostacyclin produc-
tion and more apoptosis when exposed to plasma of patients
with thrombocytopenic thrombotic purpura, whereas endo-
thelial cells derived from lungs and liver do not respond to
this same stimulus [98]. Lastly, also at the level of
transcription a differential phenotype of endothelial cells
between various organs can be demonstrated. Coagulation
proteins, such as von Willebrand factor, have been shown to
respond to various promoters by expressing this factor in
different tissues, for example exclusively in heart and
skeletal muscle or in brain [90].
Coagulation activation and the kidney
Coagulation is important in two groups of renal disorders in
man. In one group, the kidney is the major site of disease,
and localized thrombosis and fibrin formation is super-
imposed on demonstrable immunological and or endothelial
damage. These disorders will not be discussed here. In the
second group, renal lesions associated with fibrin formation
are involved as a consequence of systemic intravascular
coagulation or DIC [99]. In the latter group, acute renal
failure (ARF) is the usual associated renal presentation,
occurring in the course of sepsis, major surgery, severe
trauma, and hypovolemic and cardiogenic shock. The
pathogenesis of ARF in these conditions is caused by
hypoperfusion resulting in ischemia–reperfusion injury. The
decrease in oxygen saturation and hormonal dysregulation
causes acute tubular necrosis [100]. At least in septic shock,
it has been suggested that microthrombi contribute to ARF
[101, 102]. The older literature strongly suggests that
intravascular coagulation causes immediate changes that
are detrimental to renal function. Electron microscopical
studies have shown that coagulation causes mesangial
swelling and an increase in vacuoles, organelles free
ribosomes, and mitochondria [103]. These changes were
associated with phagocytosis of fibrin and secretion of
basement membrane-like material. The glomerular lesions
occurring in the course of DIC may resemble those seen in
acute glomerulonephritis, with platelets and fibrin deposits
intraluminally, swollen endothelium, subendothelial depos-
its of fibrin cleavage fragments, and cellular proliferative
effects. When these processes continue, complete occlusion
of glomerular capillaries and hyalinization of glomeruli
may follow [99]. The pathophysiology of renal failure in
shock is also thought to be influenced by vasoactive
substances, and renal damage was markedly reduced by
adrenergic blockade in a model of hemorrhagic shock or
endotoxin shock [104]. Catecholamine infusion in experi-
mental animals causes shock and DIC. Heparin reduces the
effects of catecholamine-induced shock and endotoxin-
related complications in animal models. It thus appears
that the combination of hypoperfusion-related ischemia–
reperfusion injury and vasoactive reactions are of major
influence on the occurrence of ARF in shock. The finding
of fibrin deposits suggests that DIC contributes to organ
damage, and the observed improvement under heparin
treatment supports this concept. The trigger to thrombosis
is probably locally induced by the ischemia–reperfusion
responses of hypoxia-inducible factor-mediated TF expres-
sion [105]. In addition, systemic stimuli such as endotoxin
cause cytokine-mediated upregulation of TFmRNA in the
kidney, while local fibrinolytic defense mechanisms are also
activated (u-PA and t-PA, without concurrent upregulation
of PAI-1). Furthermore, experimental studies have demon-
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reduced fibrin in the kidney [106]. Infusion of hirudin
caused a dose-dependent decrease in mortality and also
reduced the amount of fibrin deposition in the kidney. An
important role of the protein C system in preventing
glomerular thrombosis may be inferred from the abundant
presence of thrombomodulin expression on endothelial
cells in the glomerulus [107]. In inflammatory glomerular
disease, such as acute membranoproliferative or lupus
glomerulonephritis, an increase in thrombomodulin expres-
sion has been implicated [108]. In contrast, in ischemia–
reperfusion injury in kidneys, thrombomodulin has been
markedly downregulated. Administration of soluble throm-
bomodulin to rats with renal ischemia–reperfusion injury
prevented massive glomerular thrombosis and kidney
dysfunction [109]. In another experimental study of renal
ischemia and reperfusion, administration of activated
protein C prevented histological changes and the decrease
in renal blood flow, and preserved kidney function, whereas
treatment with active site-blocked factor Xa, heparin, and
inactivated protein C were less effective [110]. It therefore
appears that inhibition of coagulation also reduces the
amount of fibrin in the kidney. This may imply an
improvement of renal function; however, there have been
no controlled trials in which the beneficial effect of
anticoagulant treatment in patients with DIC and ARF
was investigated.
Coagulation activation and the lung
The lungs are among the most frequently affected organs
during severe infection and sepsis [111, 112]. Lung injury in
this situation is characterized by increased permeability of
the alveolar–capillary membrane, diffuse alveolar damage,
and the accumulation of pulmonary edema, containing a
high concentration of proteases and other proteins. Patho-
logical examination of the injured lung demonstrates
epithelial cell injury represented by extensive necrosis of
pneumocytes, swelling of endothelial cells with the widen-
ing of intercellular junctions, and the formation of hyaline
membranes, for an important part composed of fibrin in
alveolar ducts and airspaces. At later stages, massive
infiltration of neutrophils and other inflammatory cells will
occur and fibrin thrombi can be seen in the alveolar
capillaries and smaller pulmonary arteries [113]. The
abundant presence of intravascular and extravascular fibrin
appears to be a specific hallmark of acute lung injury
following sepsis and is much more outspoken than the
fibrin deposition in other organs. Based on this observation,
many authors have hypothesized that fibrin deposition
plays an important role in the pathogenesis of acute lung
injury in sepsis, a concept that is further supported by large
clinical studies in patients with sepsis demonstrating the
association between lung injury and coagulation abnormal-
ities [114]. Furthermore, the extensive local fibrin deposi-
tion may suggest that local activation of coagulation or
perturbation of local physiological regulatory systems could
be involved in this. Interestingly, it has been shown that
effective blocking of the coagulopathy in experimental
sepsis attenuates lung injury and local inflammatory
activity, which may point at pivotal cross-talk between the
(local) mechanismsofcoagulation and inflammation[14, 15].
In BAL fluids from patients with ARDS, it has been
demonstrated that there is activation of coagulation and
inhibition of fibrinolysis [115–117]. Almost immediately
after onset of ARDS, an increased but transient procoagu-
lant activity can be detected in BAL fluid. At the same
time, fibrinolytic activity is strongly inhibited and is kept at
a low level up to 14 days. Experimental and clinical studies
have shown that fibrin deposition is due to tissue factor-
mediated thrombin generation and suppressed fibrinolysis
[118]. The most important determinants of these local
disturbances are TF and PAI-1; high levels of soluble TF
can be measured in BAL fluid from patients with ARDS,
while increased production of PAI-1 is the most consistent
finding reported as being related to suppressed fibrinolytic
activity. Recently, lower levels of pulmonary PC levels were
correlated with a higher degree of lung injury and worse
outcome in patients with acute lung injury [119]. Similar to
acute lung injury and ARDS, pneumonia is characterized
by a shift in the alveolar hemostatic balance. In BAL fluid
from patients with severe pneumonia, a markedly increased
procoagulant activity was detected. Concordantly, fibrinolytic
activity was depressed in BAL fluids, which is related to high
concentrations of PAI-1 in the lungs. Patients at risk for
ventilator-associated pneumonia show similar changes in
pulmonary fibrin turnover [120]. Similarly, in mechanically
ventilated patients who developed pneumonia, an increase in
coagulation products was detected in lung lavage fluids.
Interestingly, the diagnosis of pneumonia was preceded by a
strong increase in PAI-1 levels in the lungs, with a resulting
decrease in fibrinolytic activity. Similar to the inflammatory
responses in patients with unilateral pneumonia patients,
there is overt activation of coagulation and depressed
fibrinolytic activity due to PAI-1 upregulation [121]. Recent-
ly, it has been demonstrated that the protein C system is also
suppressed at the site of infection, contributing to the
procoagulant effects of pulmonary infection [121].
Coagulation activation and the intestinal tract
Acute intestinal ischemia and reperfusion may result in
impaired intestinal structure and function, in experimental
models characterized by intestinal cell swelling and protein
174 Semin Immunopathol (2012) 34:167–179leakage and impaired intestinal absorptive capacity. In
addition, intra- and extravascular fibrin deposits may be
present due to activation of mesenteric coagulation and
inhibition of fibrinolysis [122]. Upon 20 to 40 min of
occlusion of the superior mesenteric artery and subsequent
reperfusion, portal vein plasma levels of thrombin–anti-
thrombin levels increased, indicating local thrombin gener-
ation. This increase in portal coagulation activity is
associated with a marked fall in protein C activity levels.
Simultaneously, markers for fibrinolysis in portal plasma
showed a complete inhibition due to an increase in levels of
plasminogen activator inhibitor, type 1 (PAI-1). This
activation of coagulation upon ischemia–reperfusion could
be almost completely blocked by systemic administration of
activated protein C, whereas heparin and antithrombin were
less effective (Schoots et al., submitted for publication).
Interestingly, amelioration of ischemia–reperfusion-induced
intestinal intra- and extravascular fibrin deposition by
administration of activated protein C caused a significant
improvement in intestinal function.
Coagulation activation and the liver
The liver is the major site of synthesis of almost all
coagulation factors. In addition, Kupfer cells of the liver are
most important bacterial scavengers, and neutralize bacte-
rial products and pro-inflammatory cytokines. Impaired
synthesis of physiological anticoagulant proteins antithrom-
bin and protein C, and low levels of free protein S due to
acute phase upregulation of C4b-binding protein (the carrier
of protein S) are well-known consequences of impaired
liver function [123]. However, failure of the coagulation
system is not only a consequence of liver failure but may
also contribute to the pathogenesis of liver failure in
systemic inflammatory states. Under these circumstances,
endothelial cells of the liver show a marked upregulation of
tissue factor, leading to local thrombin generation and
fibrinogen to fibrin conversion [124]. A marked cross-talk
between coagulation and inflammation is also strongly
present in liver tissue, as protease-activated receptors
(PARs) are abundantly present and activated coagulation
proteases may not only lead to fibrin formation but also to
increased inflammation, and in case of liver tissue,
ultimately to tissue fibrosis [125]. Indeed, it has been
shown that anticoagulant treatment can prevent ischemia–
reperfusioninjuryinanexperimentalmodelinratlivers[126].
Conclusion
The response of the coagulation system upon systemic
inflammation may considerably vary between cells, tissues,
and organs. This may explain, in part, the variable clinical
presentation of multiple organ failure in patients with a
systemic inflammatory response upon sepsis or trauma.
Many coagulation pathways in various organs may act
according to parallel routes, but marked differences exist in
the emphasis of a specific mechanism in a specific organ
system. Detailed knowledge on the site-specific activation
and regulation of coagulation may provide more insight in
better management strategies in case of specific organ
failures in the setting of a systemic inflammatory response.
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